TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Yi-Long Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.